Why the study?
Does intravenous nifekalant improve arrhythmia suppression in patients with severe ventricular tachyarrhythmias complicating acute coronary syndrome?
Does intravenous nifekalant improve arrhythmia suppression in patients with severe ventricular tachyarrhythmias complicating acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
Intravenous nifekalant administered as a bolus followed by a low-dose continuous infusion is highly effective and safe for suppressing severe, shock-resistant ventricular tachyarrhythmias complicating acute coronary syndrome.
BACKGROUND: Intravenous amiodarone (AMD) has been used for the treatment of ventricular tachycardia/fibrillation (VT/VF) in emergency care medicine. However, AMD acts slowly and is occasionally accompanied by hypotension and bradycardia. The antiarrhythmic effect of intravenous nifekalant (NIF) was assessed in patients with VT/VF complicating acute coronary syndrome (ACS) according to our study protocol. METHODS AND RESULTS: Among a series of 1,143 ACS patients, 41 patients who suffered sustained VT/VF were enrolled; 19 failed to respond to a preceding lidocaine (LID) injection. NIF was given first as an intravenous bolus injection (0.2 mg/kg) and then as a continuous intravenous infusion at a relatively low dose level (0.2 mg x kg(-1) x h(-1)). Sustained VT/VF was successfully inhibited by NIF in 34 patients (83%). In subgroup analysis, NIF achieved VT/VF inhibition in 79% of patients who received preceding LID and in 86% of patients who received direct NIF. There were no significant changes in systolic blood pressure or heart rate following NIF therapy. A corrected QT interval was significantly prolonged (P<0.01), whereas torsade de pointes developed in only 1 patient (2%). CONCLUSIONS: An intravenous bolus injection and subsequent continuous infusion of NIF at a relatively low dosage were effective in treating severe ventricular tachyarrhythmias complicating ACS, reducing the potential risk of proarrhythmia.
No takes yet. Share an insight, caveat, or question.
Yusu et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: